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Obsessive-compulsive disorder (OCD) is characterized by recurrent intrusive ideas, 
impulses, or urges (obsessions) along with overt or covert behaviors (compulsions) aimed at 
reducing the distress (DSM-IV-TR). Patients have either obsessions, compulsions, or, most 
commonly, both. Obsessions are defined as recurrent and persistent thoughts, impulses, or 
images that are experienced as intrusive and inappropriate and cause anxiety. The 
obsessions are not simply excessive worries about real-life problems and the affected 
individual usually recognizes that these thoughts, impulses or images are excessive, 
unreasonable and a product of their own mind (DSM-IV-TR). In order to naturalize the 
obsessions, other thoughts or actions are performed (compulsions). Examples of obsessions 
include, among others, contamination (concern with dirt or germs, fear of blood) symmetry 
(concern about order, exactness), obsessions about safety and harm (fear of harm due to 
carelessness, fear of being responsible for terrible events) hoarding, pathological doubt (after 
completing a routine activity the affected individual wonders whether he or she performed 
it correctly or did it at all), numbers with special significance, etc.  
Compulsions are repetitive behaviors (e.g. hand washing, ordering, checking) or mental acts 
(e.g. praying, counting, repeating words silently) that patients with OCD feel compelled to 
do in response to an obsession, or according to rules which must be applied rigidly (e.g. 
checking that a light switch is turned off by switching it on and off without any 
interruption). The behaviors or mental acts are aimed at preventing or reducing distress or 
preventing some dreaded event or situation; however, these behaviors are either not 
connected in a realistic way with what they are designed to neutralize or prevent, or are 
clearly unreasonable or excessive. Examples of compulsive activities are washing hands 
until they are raw, repeatedly checking the locked door, arranging and rearranging items in 
a set order, counting, asking, repeating reassurance questions etc. 
The diagnosis is made by clinical interview, with a specific and detailed focus on OCD. To 
diagnose the disorder according to the DSM-IV criteria, the patient must suffer from either 
obsessions or compulsions that cause great distress, are time-consuming (more then 1 hour 
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per day), or substantially interfere with normal function, and that, at some point of the 
disorder, are recognized as excessive or unreasonable. The Yale-Brown obsessive-
compulsive scale (Y-BOCS) is regarded as the gold standard measure of obsessive-
compulsive symptom severity and is used in most treatment trials (Goodman et al., 1989). 
2. OCD treatment: First-line treatments and first-line treatments choice    
The first case report indicating that the tricyclic antidepressant (TCA) clomipramine might 
have some benefit in patients with OCD was published more than 40 years ago (Fernandez 
et al., 1967), but more than 20 years passed before clomipramine was approved for the 
treatment of OCD (Thorén et al. 1980). 
Since then, a wide number of researchers have been working in order to find effective 
pharmacological treatments, and despite treatment resistance still being a core issue in the 
therapeutic process, many goals have been achieved. Nowadays the clinician has the 
possibility of choosing a variety of treatment strategies that are effective in about the half of 
the patients (Pallanti et al. 2002). Both cognitive-behavioral therapy (CBT) and serotonin 
reuptake inhibitors (SRI) are considered valuable and safe first-line treatments for obsessive-
compulsive disorder (Koran et al., 2007). 
A broad range of factors may have an influence on the choice of the treatment strategy 
adopted by the clinician. Some of them are the severity of the symptoms, the characteristics 
of psychiatric or medical comorbidity and the relative treatment, the possibility to get a 
CBT, past and actual treatment and patient’s preference. Given the fact that most of the trials 
are based on 3-4 months long observations, there are no reliable data concerning the best 
options for long-term therapies. 
Behavioral therapy seems to be the most effective kind of psychotherapy, in particular 
exposure and response prevention (ERP) techniques (Abramowitz, 1998; Eddy et al., 2004; 
Fisher et al., 2005; Meyer, 1966). Also cognitive approaches, aiming at the identification and 
modification of dysfunctional beliefs and thoughts are considered appropriate strategies if 
coupled to the behavioral ones: in fact, only a small amount of data supports the efficacy of 
the cognitive techniques alone. 
CBT with ERP is indicated as first-line treatment for patients without particular depressive or 
anxious symptoms, for those whose disorder’s severity does not interfere with the therapeutic 
process, and in those who refuse a pharmacological treatment (Koran et al., 2007). 
Although there are no sufficiently controlled trials to provide solid evidence, the experts 
agree on the optimal duration of the treatment, which should at least consist of 13-20 
sessions (Koran et al., 2007). 
The use of a SRI without CBT intervention is indicated for those patients who were already 
treated in the past with a drug with good results or that prefer an exclusive pharmacological 
treatment. However, an initial approach with a SRI may be helpful in comprehensively 
increasing the compliance of the patient to all the components of the treatment, as an effect 
of the reduction of the symptoms’ severity. Therefore, the use of a SRI alone is indicated also 
for the patients who are not eligible for a CBT intervention because of their scarce 
compliance and collaboration or when psychotherapy is not available (Koran et al., 2007). 
The Food and Drug Administration (FDA) have approved clomipramine, fluoxetine, 
fluvoxamine, paroxetine and sertraline for the treatment of obsessive-compulsive disorder. 
There are sufficient evidences that support the efficacy of citalopram and escitalopram, 
although the FDA still does not approve them.  
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Citalopram is the most selective serotonin reuptake inhibitor. Its efficacy and safety as first 
line treatment or in case of treatment-resistance for OCD has been proved in various single 
and double blind trials (Marazziti et al, 2001; Pallanti et al, 1999; Pidrman et al., 1997; 
Stengler-Wenzke et al., 2006).  
Montgomery et al. (Montgomery et al., 2001) confronted in a double-blind trial the efficacy 
of different citalopram dosages (20, 40, 60 mg/die) and placebo; the Authors reported the 
effectiveness of all of the three dosages, with a slight advantage for the higher one, 
particularly in terms of rapidity of response. 
Escitalopram is the left enantiomer of citalopram; due to the fact that the right enantiomer 
(that contrasts the effect of citalopram on serotonin) is not included in the drug, 
escitalopram has a greater re-uptake blocking efficacy. 
A series of open and retrospective studies supports the potential efficacy of citalopram in 
OCD (Dougherty et al., 2009; Galvao-de Almeida et al., 2007; Rabinowitz et al., 2008; Shim et 
al., 2008). These results have been confirmed by two double-blind placebo controlled trials 
(Kahn et al., 2007; Stein et al., 2007). Stein et al. recruited 466 patients with a diagnose of 
OCD that were randomly treated with escitalopram 10 or 20 mg/die, paroxetine 40 mg/die, 
or placebo for 24 weeks. After 12 weeks of therapy, the mean Y-BOCS score reduction in 
comparison with placebo was of 3.21 points (p<0.1) for escitalopram 20 mg and 2.47 point 
(p<0.5) for paroxetine 40 mg. After 24 weeks there was a statistically significant difference 
for all the groups in comparison with placebo (p<0.5 for escitalopram 10 mg, p<0.1 for 
escitalopram 20 mg and paroxetine); the mean Y-BOCS score reduction was of 3.10 points 
for escitalopram 10 mg, 3.12 for escitalopram 20 mg and 4.24 for paroxetine 40 mg. 
Escitalopram was better tolerated when compared with paroxetine, as proved by the smaller 
number of treatment withdrawals caused by adverse effects, although this difference was 
not statistically significant. Moreover, escitalopram has been proved to be effective in the 
long-term treatment and in the prevention of the exacerbation of the obsessive-compulsive 
symptoms after treatment discontinuation (Fineberg et al., 2007). 
With regards to the supposed superiority of Clomipramine (CMI) over SSRIs clear evidences 
are still lacking. Nevertheless, the experts agree on the fact that SSRIs have to be considered 
first-choice treatments because of their more favorable side-effects profile (Koran et al., 
2007). The efficacy of the different SSRIs does not differ in a critical way from one to 
another, but the response may be patient-specific. The reasons of this issue are still not clear 
and accurate predictors of response to be used in the clinical practice are still lacking. 
Important aspects to be considered when choosing a SSRI are the tolerability for the individual 
patient of the specific side-effects of the drug, previous treatments and relative responses to 
them, the presence of psychiatric or medical comorbidities (i.e. paroxetine should never be 
prescribed to patients suffering from diabetes or neurologic bladder, as it is the SSRI most 
frequently associated with weight gain and anticholinergic effects (Koran et al., 2007). 
The duration of the therapy and the dosage of the chosen drug represent two features of 
primary importance in the treatment of OCD. In fact, in order to obtain a clinical response in 
OCD the usual settings fixed for depression or other anxiety disorders are not functional.  
Most of the patients do not achieve particular symptomatology improvements before 4-6 
weeks of treatment, but some of them don’t obtain it even before 10-12 weeks from the 
beginning of the therapy. 
Thus, 12 weeks is the minimal duration of treatment necessary to correctly estimate the 
efficacy of a drug and plan long-term strategies. Instead, in order to obtain the full response 
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6 months are necessary: consequently, the treatment of the acute phase of the disorder 
should be administered for at least 6 months at full dose (Zohar et al., 2007). 
With regards to the dosages, these are considerably higher that the ones used for depression 
and other anxiety disorder and often is necessary to prescribe the maximal dose in order to 
obtain a good response (Koran et al., 2007). In the following table (Table 1) the dosage 
details of the most commonly used SRIs are illustrated. 
 
SRI Starting dose (mg/day) Usual target dose (mg/day) Maximum dose (mg/day) 
Citalopram 20 40-60 120 
Escitalopram 10 20 60 
Fluoxetine 20 40-60 120 
Fluvoxamine 50 200 450 
Paroxetine 20 40-60 100 
Sertraline 50 200 400 
Clomipramine 25 100-250 300 
Table 1. (Modified by that of Koran et al. (Work group on obsessive-compulsive disorder): 
Practice guideline for the treatment of patients with obsessive-compulsive disorder. 2007) 
(American Psychiatric Association) 
In case of adequate response to the first-choice drug, the duration of the maintaining phase 
of the treatment should last not less than 2 years at the dose necessary to elicit the clinical 
response. After this period, if relapse and symptom exacerbation have not occurred, is 
possible to slowly reduce the dose over some months, strictly monitoring the course of the 
disorder, otherwise the treatment should be continued. 
A careful planning of long term treatment should consider the possibility of using lower 
doses of that used in the acute phase of the disorder. If many authors suggest keeping the 
dosage always at the same level, others state that is possible to greatly reduce it after the 
acute phase. In this perspective, it seems sensible to consider the efficacy and the tolerability 
of the therapy during the previous stages of the illness as the main guidance criteria, 
reducing the daily dose only in patients that achieve a complete, stable and long-lasting 
recovery after the treatment of the acute phase or in that patients that do not well tolerate 
high dosages of SRIs. 
Other drugs have been proposed as first-line treatment in the acute phase of OCD, even if 
no clear evidence about their efficacy is available. 
Increasing attention has been paid to the possible role of serotonin–norepinephrine reuptake 
inhibitors (SNRIs) in patients with OCD. The first evidence of the effectiveness of these 
compounds came from the observation that clomipramine is an inhibitor of the reuptake of 
serotonin as well as of norepinephrine (Dell’Osso et al., 2006). Venlafaxine is a 2-phenyl-2 
ethylamine derivate that is chemically unrelated to tricyclic, tetracyclic or other available 
antidepressant. It shows different degrees of serotonin, norepinephrine and dopamine 
reuptake inhibition, as a function of the dosage (at higher dosis, the action on the 
noradrenergic and dopamine system becomes more marked) (Dell’Osso et al., 2006). 
Although mostly not placebo-controlled, the majority of venlafaxine short and intermediate-
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term trials suggests the efficacy of this drug in both treatment-naïve and treatment-resistant 
OCD patients (Dell’Osso et al., 2006). Venlafaxine was as effective as paroxetine and 
clomipramine, and it was generally well tolerated by patients. However, due to the absence 
of double-blind placebo-controlled trials, venlafaxine should not be considered a first line 
medication treatment for patients with OCD at this time. Perhaps venlafaxine might be 
considered in specific clinical situations such as OCD with comorbid 
attention/deficit/hyperactivity disorder (ADHD) (Dell’Osso et al., 2006). 
One placebo-controlled trial supports the efficacy of phenelzine (MAO inhibitor) (Vallejo et 
al., 1992). However, another one that compared phenelzine both to fluoxetine and to placebo 
demonstrated superiority over placebo for fluoxetine but not for phenelzine (Jenike et al., 
1997).  
Mirtazapine is an antidepressant that does not enhance 5-HT neurotransmission directly, 
but disinhibits the norepinephrine activation of 5-HT neurons and thereby increases 5-HT 
neurotransmission by a mechanism that does not require a time dependent desensitization 
of receptors (unlike SSRIs). The treatment of OCD patients has been tested in a single-blind 
study, which compared citalopram alone to a combination of mirtazapine and citalopram. 
This study indicated that the responses were faster (after four weeks) but that there was no 
difference between the groups after eight weeks and twelve weeks (Pallanti et al., 2004). 
Another open study showed the superiority of mirtazapine to placebo (Koran et al., 2005). 
3. Approaches to treatment resistance and pharmacological strategies in 
resistant-OCD 
Even if SSRIs have brought to a significant progress in the treatment of OCD, clinical 
evidence suggests that a high percentage of patients, ranging from about 40% to 60%, does 
not reach satisfying clinical improvement and does not “respond” properly to therapy 
(CMI-group, 1991; Goodman et al., 1992; Jenike and Rauch, 1994; McDougle et al., 1993; 
Piccinelli et al., 1995; Pigott et al., 1999; Rasmussen et al., 1993), with a strong impact on their 
quality of life, both in terms of disability and morbidity (Hollander et al., 1996). 
We introduced operational criteria for the evaluation of the different “stages of response” in 
order to provide to the clinician a template to organize the best treatment strategy (Pallanti 
et al., 2002). The response to treatment is seen as a continuum of steps that ranges from the 
worse outcome, the refractoriness to all type of therapies, to the best outcomes,  “remission” 
and “recovery”. 
Some terminological issues need to be clarified in order to avoid misunderstandings. 
The term “resistant” should be used in case of a fail of one trial of therapy with a first choice 
treatment (at least 10-12 weeks with full dose of an SRI), whereas “refractory” only after at 
least three trials with SRI agents (one of them with Clomipramine), two augmentation trials 
with atypical antipsychotics, and at least 20-30 hours of cognitive-behavioral therapy.  
Also the concept of “recovery” is different from that of “remission”, although in OCD this 
last one seems to be a rare event; episodic course has been described in adults (Perugi et al., 
1998; Ravizza et al., 1997) and because of this, the introduction of these two different 
definitions in the staging of illness seems to be rational and practical, as proposed by Frank 
et al. (1991) for depression.  
“Recovery” should be used in case of complete absence of symptoms after treatment, 
corresponding to a Y-BOCS score of less than 8. Unfortunately, full recovery concerns only 
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the 5% of patients with an episodic course of OCD (Rasmussen and Eisen 1997). The most 
probable result in a case of non-episodic courses is instead “remission”, that indicates a 
reduction of the symptoms after treatment to the lower limit, which corresponds to a Y-
BOCS score of 16 or less (see Table 2). 
The presence of comorbid conditions also influences the course of the response to treatment. 
Non-responsive patients are more likely to meet criteria for comorbid psychiatric disorders 
and the presence of a specific comorbid condition could be a distinguishing feature in OCD, 
with influence on the treatment adequacy and outcome (Pallanti & Quercioli, 2006). For 
example, conditions such as bipolar disorder and ADHD (attention deficit hyperactivity 
disorder) are common in treatment-resistant patients, but there are only few studies 
investigating their impact on treatment resistance (Magalhães et al., 2010; Sheppard et al., 
2010).  
The majority of the proposed treatment-resistance therapeutic options are not FDA approved, 





I Recovery Not at all ill; less than 8 on Y-BOCS 
II Remission Less than 16 on Y-BOCS 
III Full Response 
35% or greater reduction of  
YBOCS and CGI 1 or 2 
IV Partial Response 
Greater than 25% but less than 35%  
YBOCS reduction 
V Non-response Less than 25% YBOCS reduction, CGI 4 
VI Relapse 
Symptoms return (CGI 6 or 25% increase in  
Y-BOCS from remission score) after 
3+ months of ‘‘adequate’’ treatment 
VII Refractory 
No change or worsening with  
allavailable therapies 
Table 2. Stages of response  
3.1 Switching 
Switching consists in replacing a serotoninergic agent with another one, or with a molecule 
of another class of drugs. The successfulness of this strategy in resistant patients is 
suggested by a number of studies (Ackerman et al., 1998; Denys et al., 2004; Goodman et al., 
1997; Hollander et al., 2002; Koran et al., 2006; Rasmussen et al., 1997), but is not possible to 
predict the response of the patient to another drug. As suggested by clinical experience, the 
response rate to a successive treatment is around 50%, but it also declines with an inverse 
relationship to the number of failed trials (Koran et al., 2007). 
The majority of the authors suggest switching from a SSRI to clomipramine (CMI) or vice 
versa, while the advantages of shifting from a SSRI to another one still remain unclear 
(Bogetto et al., 2003; Koran et al., 2007). The only data available are that of an open-label trial 
showing that a non-response to a SSRI does not imply the non-response to other molecules 
of the same class: 18 non-responders patients to at least two SSRI trials were treated with 
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citalopram 40 mg/die and a response rate of 77% was obtained (Marazziti et al., 2001). In a 
case series, switching from SSRIs to the SNRI duloxetine was successful in a number of 
treatment-resistant patients (Dell’Osso, 2008). Some other trials have been performed with 
venlafaxine and mirtazapine. The switch from venlafaxine to paroxetine showed an 
improvement in 56% of the cases after the treatment, while from paroxetine to venlafaxine 
the rate was only 19% (Denys et al., 2004). The switch to mirtazapine is supported by one 
open pilot study and a double blind discontinuation trial (Koran et al., 2005).  
So, considering the fact that there are no double blind studies that confirm the efficacy of 
switching a SSRI with another one, the rationale of this strategy derives from pharmacokinetic 
and side-effects issues. Citalopram and sertraline are for example poor inhibitors of the cit. P-
450, which is involved in the metabolism of largely prescribed drugs, and could be therefore 
used in cases of complex pharmacological interactions. Instead, fluoxetine and paroxetine 
significantly inhibit the enzymes CYP2D6, that metabolize tricyclic antidepressants, 
antipsychotics, antiarrhythmic drugs and beta-blockers; fluvoxamine inhibits CYP1A2 and 
CYP3A4, which are implicated respectively in the elimination of warfarin and tricyclic 
antidepressants, benzodiazepines and antiarrhythmic drugs. Fluoxetine has a long half-life 
and an active metabolite that reduces the effects of abstinence, and this could result useful in 
patients with a low compliance (Pallanti & Koran, 2003).  
3.2 Augmentation   
3.2.1 SRIs 
This augmentation strategy consists of the combination of two serotoninergic drugs, usually 
clomipramine or SSRIs, depending on which was the initial agent. Sertraline and citalopram 
represent first choice SSRIs augmentation molecules to clomipramine, due to the fact that 
they have a minor inhibitor effect on cit P-450 (Bogetto et al., 2003). The efficacy of 
clomipramine as augmentation agent to SSRIs is supported by a number of studies (Pallanti 
et al., 1999; Ravizza et al., 1996; Szegedi et al., 1996) and by a large expert-consensus (Koran 
et al., 2007). It’s recommended to check the plasmatic concentration of clomipramine and of 
his metabolite desmethyl-clomipramine during an augmentation therapy and keep it below 
500 ng/ml, because of cardiac and CNS toxic side effects. Fluvoxamine seems to be the SSRI 
that primarily has such an increasing effect (Koran et al., 2007). 
With regards to the efficacy of SSRI augmentation during clomipramine treatment, research 
has focused on sertraline and fluoxetine. In an open trial a 20-40 mg dose of fluoxetine was 
effective in clomipramine-resistant patients (Simeon et al., 1990) and sertraline 
augmentation was more effective when compared to the dosage increase of the first choice 
treatment (Ravizza et al., 1996). 
Besides SSRIs, a number of studies have been performed in the last years to investigate the 
usefulness of other serotoninergic drugs, but the results are not clear and need further 
investigations before being considered as standard treatments. 
3.2.2 Dopaminergic agents 
The dopaminergic system has a central role in the pathophysiology of OCD, as supported 
by pre-clinical and clinical evidences. Experimental studies in animals, using dopaminergic 
drugs (amphetamine, bromocriptine, apomorphine and L-dopa), have provided evidence 
for the dopamine involvement in compulsive behaviors such as grooming and repetitive 
checking behaviors, which are commonly considered animal models of OCD (Denys et al 
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2004; Pitman 1989; Tizabi 2002). Several evidences of dopamine dysregulation in OCD have 
also been found in humans. An indirect strong evidence of the role of dopamine in OCD is 
provided by some neurological diseases associated with dopaminergic dysfunction such as 
Tourette's syndrome, Sydenham's chorea and Parkinson disease, which often show 
obsessive-compulsive symptoms in their clinical presentation (Lochner et al., 2005; Pauls et 
al., 1986, 1995); in addition, Tourette's Syndrome and OCD are supposed to share common 
neurobiological underpinnings and genetic factors, due to the fact that they are described as 
comorbid, mainly in the childhood-onset forms (Perani et al. 2008). Moreover, the increase 
in synaptic dopamine levels due to the effect of drugs such as cocaine and amphetamines 
have been reported to exacerbate or induce as well as to improve OCD symptoms 
(Westemberg et al. 2007).  Also neuroimaging studies provide interesting data about the 
dopamine involvement in OCD. Recently Perani et al. (Perani et al. 2008) conducted a 
positron emission tomography (PET) study in drug-naïve OCD patients, measuring both 
serotonin (5HT2A) and dopamine (D2) receptors distribution in vivo. The observed 
reduction of D2 receptors binding potential suggests a dopaminergic dysfunction, in 
particular in the ventral portion of striatum.  
3.2.2.1 Antipsychotics 
The effectiveness of antipsychotics augmentation in OCD treatment-resistant patients has 
been tested in many studies. Evidences of the efficacy of haloperidol and risperidone are 
provided by some randomized double-blind placebo-controlled studies; nevertheless, data 
regarding the effectiveness of quetiapine and olanzapine are still open to question. The 
effect of antipsychotics augmentation on OCD symptoms is relative quick, and patients are 
unlike to improve if they have not responded after one month of intervention (Bloch et al. 
2006). The reason of the greater haloperidol and risperidone effectiveness is probably that 
they have a greater D2-dopamine receptor affinity. Preliminary available data highlight 
interesting perspectives regarding the use of new agents such as aripiprazole, although they 
do not provide yet sufficient basis for their wide use in OCD. The identification of predictors 
of antipsychotics response would represent a relevant progress in the treatment of resistant 
patients but unfortunately at the moment there is no reliable evidence regarding this issue. 
However, several data show that the subgroup of OCD patients with comorbid tics have 
particularly beneficial response to this intervention (especially to haloperidol) as well as 
those with poor insight (Hollander et al. 2003) and co-occurring schizotypal personality 
disorder (Bogetto et al. 2000; McDougle et al., 1990).  
Until recently, mainly short-term response data were produced with regards to 
antipsychotics augmentation. Matsunaga et al. (2009) conducted the only available trial 
concerning the effectiveness and safety of long-term atypical antipsychotics augmentation. 
SRI-resistant patients responded to augmentation with atypical antipsychotics but showed a 
significantly higher rate of body mass index, as well as a significantly higher level of fasting 
blood sugar or elevated levels of triglycerides and total cholesterol, when compared to SRI-
responders. These data are consistent with previous findings from short-term clinical trials 
and emphasize the importance to assess the metabolic and nutritional aspects in the 
management of OCD treatment-resistant patients. 
3.2.2.2 Dextroamphetamine and caffeine 
A single 30 mg dose of dextroamphetamine (d-amphetamine) was superior to placebo in 
immediately relieving OC symptoms in two small double blind placebo-controlled studies 
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conducted before the introduction of SSRI for OCD treatment (Insel et al., 1983; Joffe et al., 
1991). Methylphenidate monotherapy was effective in two cases of comorbid attention-
deficit/hyperactivity disorder (ADHD) and OCD (van der Feltz-Cornelis, 1999). 
Nevertheless, in another open-label study, methylphenidate (40 mg) had no significant 
effect on OCD symptoms (Joffe et al., 1987).  
Recently Koran et al. (2009) conducted a 5-week, double-blinded, caffeine controlled study 
of d-amphetamine augmentation in treatment-resistant OCD. Caffeine appeared to be 
slightly more effective, in both terms of number of responders (33% for d-amphetamine and 
50% for caffeine) and degree of response (mean Y-BOCS score decrease was 48% for d-
amphetamine and 55% for caffeine). The OC symptoms improvement associated with both 
drugs was maintained or increased over all the duration of the study. A possible 
explanation for the mechanism of this therapeutic effect could be that the increased release 
of dopamine induced by both drugs may increase D1 receptor stimulation in the prefrontal 
cortex; this enhancement is associated with improved attention regulation and working 
memory in patients with ADHD (Arnsten, 2006) that could lead to fewer obsessive 
intrusions, increased ability to shift attention away from them, and thus, decreased urges to 
perform compulsions (Koran et al., 2009). 
3.2.3 Opioids 
A remarkable number of studies (both preclinical and clinical) suggest the involvement of 
the opioid system in the pathophysiology of OCD (Amiaz et al., 2008; Koran et al., 2005b; 
McDougle et al., 1999; Roy et al., 1994; Urraca et al., 2004, Warneke et al., 1997). At the 
moment the results of the clinical trials concerning the use of opioid drugs as augmentation 
strategy in treatment-resistant OCD are controversial and there is no sufficient evidence 
supporting its use. Morphine, lorazepam and placebo were compared in a double blind 
study (Koran et al., 2005b) but only one patient had a sufficient response to morphine. 
Shapira and colleagues provided a report of the efficacy of the opioid agonist tramadol (26% 
reduction of the Y-BOCS score after 2 weeks of treatment) (Shapira et al., 1997). The opioid 
antagonist naltrexone did not improve OCD symptomatology and caused a worsening of 
anxiety and depressive symptoms in a double blind trial (Amiaz et al., 2008). 
3.3 Infusion therapy 
Infusion therapy is widely considered as a valid therapeutic strategy for treatment-resistant 
cases; clomipramine and citalopram are the drugs currently available for this kind of 
treatment. 
The absorption of an intravenous administered drug is rapid, constant, and complete and is 
not affected by gastrointestinal variables, simultaneous administration of other drugs and 
first pass metabolism. Moreover, from a clinical point of view infusion therapy may 
improve treatment compliance, reinforce the therapeutic alliance and reduce the frequency 
of adverse events.  
A greater efficacy of clomipramine i.v. versus placebo was reported in a double-blind 
placebo controlled study on 54 non-responders patients (in a previous 8 weeks-long trial 
with clomipramine per os) (Fallon et al., 1998). This could be explained considering the fact 
that the metabolite desmethyl-clomipramine has a weaker serotoninergic effect than 
clomipramine and intravenous administration may therefore increase the plasmatic 
clomipramine/desmethyl-clomipramine ratio and enhance the therapeutic effect. 
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Koran et al. (1998) compared clomipramine gradual increase administration and “pulse 
loading” administration. The results suggest a faster response with pulse loading 
administration. “Pulse loading” strategy consists in the application 150 mg i.v. at the first 
day, 200 mg i.v. at the second day, no administration for four consecutive days and then oral 
administration.  
At the present time citalopram is the only SSRI available for infusion therapy. Our group 
administered for three weeks intravenous citalopram (followed by oral administration for 
other 9 weeks) to treatment-resistant OCD patients that were non-responders in at least two 
adequate trials with SSRI but not citalopram: 59% of the patients showed a reduction of at 
least 25% of the initial Y-BOCS score after the first 3 weeks of therapy, and improved more 
at the end of the 12 weeks (Pallanti et al., 2002b). 
4. Physical therapies 
4.1 Deep brain stimulation (DBS) 
Another option to the neurosurgical interventions performed as last resource in 
treatment-resistant patients with extremely disabling symptoms is represented by deep 
brain stimulation. In deep brain stimulation (DBS) procedures, stimulation electrodes are 
implanted into specific brain regions and continuous electrical high frequency stimulation 
is delivered from a pulse generator. DBS is externally programmable and reversible, in 
that the stimulator can be turned on or off and controlled at the discretion of the clinician. 
The targets that have shown to provide the best results are both the anterior limbs of the 
internal capsule. The stimulation of this area seems to disrupt the activity in the loop 
fibers that connect the cortex with the thalamus and therefore interrupt the pathological 
circuit of this area (Shah et al., 2008). DBS in this site was successful in several case series 
(Abelson et al., 2005; Anderson and Hamed, 2003; Gabriels et al., 2003; Nuttin et al., 1999, 
2003, 2008).  In an open study, DBS was still effective after three years from the 
implantation (Greenberg et al., 2006). A multicenter randomized sham-controlled 
crossover study based on the stimulation of the subthalamic nucleus on 16 patients with 
severe OCD showed interesting results (Mallet et al., 2008). After 10 months of active 
stimulation 10 patients had a significant improvement of the symptoms and 4 recovered 
(Y-BOCS of 6 or less). However, the good results of this study are limited by the onset of 
some major adverse events (including a brain hemorrhage) and several minor adverse 
events.  
4.2 Repetitive transcranial magnetic stimulation (rTMS) 
There is no clear evidence regarding the use of rTMS in the treatment of OCD due to the fact 
that the design of the few studies performed differs in many important aspects such as site 
stimulation, parameters, and treatment duration. In double-blind sham-controlled studies, 
rTMS was ineffective both over the left dorsolateral prefrontal cortex was ineffective (Prasko 
et al. 2006; Sachdev et al. 2007) and over the right prefrontal rTMS (Alonso et al., 2001). 
Finally, interesting results were provided by two recent studies concerning the stimulation 
of the orbitofrontal cortex (Ruffini et al., 2009) and of the supplementary motor area 
(Mantovani et al., 2010) that showed a significant reduction of Y-BOCS score when 
compared to sham stimulation.  
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4.3 Electroconvulsive therapy (Ect) 
Experts agree on the fact that ECT has a very limited role in OCD treatment, as there is no 
relevant evidence of benefits regarding the control of core symptoms of OCD (Bandelow et 
al., 2008) even if some case reports suggest the efficacy of it (Fukuchi et al., 2003; Strassnig et 
al., 2004;). Anyway, it may represent a useful tool for the treatment of OCD comorbidities 
such as depression, catatonia, etc. (Casey & Davis, 1994; Hanisch et al., 2009). 
5. Conclusions and future perspectives 
In conclusion, the range of therapeutic options for treatment-resistant patients is wide, and a 
number of them seem to have a quite good efficacy. Current research on animal and human 
models suggests that the discovery of more precise and distinctive neurofunctional targets is 
possible and that may successfully lead to a patient-tailored treatment algorithm. 
Identifying the different groups of patients and basing the treatment on reliable and easily 
detectable neurodysfunctional targets is one of the most desirable and exciting goals that in 
the next future may be achieved, in order to offer a highly specific treatment for each single 
patient. 
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